Literature DB >> 24642023

Xylometazoline poisoning: A 40-fold nasal overdose caused by a compounding error in 3 children.

Frank Musshoff1, Burkhard Madea2, Joachim Woelfle3, Dejan Vlanic3.   

Abstract

The imidazoline derivative xylometazoline, an alpha-2-adrenergic agonist, is used as non-prescription nasal preparation due to its vasoconstrictive and decongestive properties. Especially in children, an overdose can quickly cause severe central nervous system depression and cardiovascular adverse effects. In three 3-year-old boys (triplets) a xylometazoline intoxication was diagnosed by toxicological analysis. On admission to an emergency unit all three children were still unresponsive. One triplet showed respiration of 15-20 breaths/min and required oxygen support (3L/min) via face mask; his electrocardiogram revealed sinus bradycardia of 64 beats/min with supraventricular extrasystoles. However, no interventions were necessary except fluid management via intravenous lines. Eleven hours after the event, two of the triplets were awake but still not fully oriented. The third triplet woke up 20h after instillation of nose drops. Intoxication was caused by a compounding error in a pharmacy resulting in a concentration 40 times above the adequate dosage for children. In general, physicians, pharmacists and the public should be educated about the toxicity of over-the-counter preparations.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Children; Compounding error; Intoxication; Xylometazoline

Mesh:

Substances:

Year:  2014        PMID: 24642023     DOI: 10.1016/j.forsciint.2014.02.011

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  2 in total

1.  Design of a Precision Medication Dispenser: Preventing Overdose by Increasing Accuracy and Precision of Dosage.

Authors:  Shriya S Srinivasan; Sai N R Kantareddy; Ebenezer A Nkwate; Praveen Meka; Ivy Chang; Nevan C Hanumara; Khalil B Ramadi
Journal:  IEEE J Transl Eng Health Med       Date:  2018-06-19       Impact factor: 3.316

Review 2.  Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.

Authors:  JoAnn V Pinkerton; James H Pickar
Journal:  Menopause       Date:  2016-02       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.